Who Holds the Precious Ring
الخميس، ٥ نوفمبر ٢٠٢٦
Dear reader, a pharmaceutical company has bought a piece of a jewelry maker, and the transaction tells you more about where medicine is going than most of what was announced this year.
On 15 July 2026, Eli Lilly, one of the world's largest pharma companies, made an equity investment in Oura, the Finnish-founded company now headquartered in Oulu and San Francisco, whose smart ring continuously measures sleep, heart rate, heart rate variability, body temperature trends, and movement. The investment came as part of Oura's Series E round; neither the size of the stake nor the valuation was disclosed. It came three weeks after a commercial partnership announced on 23 June: users of LillyDirect, the company's own direct-to-consumer platform, became eligible for a free Oura Ring sizing kit, normally a ten dollar item, and a month earlier, in late May, Oura had launched GLP-1 Insights, a feature letting users log GLP-1 doses, track side effects, and follow weight alongside their sleep, activity, readiness, and stress data. More than 100,000 Oura members have now logged GLP-1 use in the app. Both companies stated at the time that the collaboration did not involve sharing user data.
Why would the largest company in the obesity drug market by revenue want a foothold in a smart ring? The clinical answer is a good one. These medicines work, but the loss is not all fat: without deliberate protein and resistance training, a substantial share of the weight lost is lean mass, and that matters most in the older patients who need the drug most. Appetite suppression can also reduce total intake below the body’s requirements. Sleep is often disturbed early in titration, and activity may fall rather than rise. None of that appears on a monthly clinic scale, and all of it appears in continuous data.
The commercial answer is equally good and less often stated. The weak point of this entire category is not efficacy but persistence. A large fraction of patients stop within the first year due to cost, side effects, or a plateau: on IQVIA's numbers, only about a third are still taking the medicine at 13 months. Every discontinuation is lost revenue and often regained weight. Anything that keeps a patient engaged and feeling progress on days when the scale is flat is worth a great deal to the manufacturer. A ring that says your resting heart rate has fallen and your sleep has improved is telling the truth and also making a sale.
This is why the equity investment matters more than the partnership did. A partner is a vendor you can drop. An equity holder is a stakeholder in the other company's strategy and its valuation. When the maker of the drug owns part of the maker of the instrument that measures the drug's effects, the relationship between measurement and marketing needs to be governed explicitly rather than assumed. To be fair to both, they said at the outset that data would not flow between them, and I have no reason to doubt it. But a policy is not an architecture, and the useful question is not what it says today but what would have to happen for it to change.
Step back, and the pattern is clear. LillyDirect launched in January 2024, added a nutrition partner, Nourish, that November, a behavioral health partner, Thrive Global, the following January, then retail pickup, and now wearables. Its competitors are building the same thing from the other end: digital health platforms that started with consultations and are moving toward pharmacy, labs, and their own algorithms. Both are converging on a single destination: an ecosystem in which diagnosis, prescription, delivery, and monitoring are handled by a single commercial entity, with the patient at the center and the independent clinician somewhere off to the side.
For this region, the relevance is immediate. Gulf adoption of wearables is among the highest in the world, our obesity prevalence likewise, and GLP-1 demand here has run ahead of the systems meant to supervise it. A ring that tracks a patient through therapy is an excellent thing in a market where follow-up is thin. But three questions should be settled first: where the physiological data of Saudi patients is stored and under whose jurisdiction, given that the Personal Data Protection Law has been fully enforceable since September 2024 and SDAIA has yet to publish an adequacy list, so each transfer abroad still needs its own approved safeguard, whether the insight a patient receives comes from a clinical model or a commercial one, and who is accountable when the device is wrong.
None of this makes the ring a bad instrument. Continuous physiological monitoring is among the more useful developments of the past decade, and a better source of evidence than the annual check-up it may replace.
Dear reader, the caution is narrower than a rejection. The value of a measurement depends on the independence of whoever is holding the instrument. When the company that sells the treatment also owns a share of the device that tells you the treatment is working, nothing has necessarily gone wrong, but something has certainly changed, and it deserves to be said out loud rather than discovered later.
On 15 July 2026, Eli Lilly, one of the world's largest pharma companies, made an equity investment in Oura, the Finnish-founded company now headquartered in Oulu and San Francisco, whose smart ring continuously measures sleep, heart rate, heart rate variability, body temperature trends, and movement. The investment came as part of Oura's Series E round; neither the size of the stake nor the valuation was disclosed. It came three weeks after a commercial partnership announced on 23 June: users of LillyDirect, the company's own direct-to-consumer platform, became eligible for a free Oura Ring sizing kit, normally a ten dollar item, and a month earlier, in late May, Oura had launched GLP-1 Insights, a feature letting users log GLP-1 doses, track side effects, and follow weight alongside their sleep, activity, readiness, and stress data. More than 100,000 Oura members have now logged GLP-1 use in the app. Both companies stated at the time that the collaboration did not involve sharing user data.
Why would the largest company in the obesity drug market by revenue want a foothold in a smart ring? The clinical answer is a good one. These medicines work, but the loss is not all fat: without deliberate protein and resistance training, a substantial share of the weight lost is lean mass, and that matters most in the older patients who need the drug most. Appetite suppression can also reduce total intake below the body’s requirements. Sleep is often disturbed early in titration, and activity may fall rather than rise. None of that appears on a monthly clinic scale, and all of it appears in continuous data.
The commercial answer is equally good and less often stated. The weak point of this entire category is not efficacy but persistence. A large fraction of patients stop within the first year due to cost, side effects, or a plateau: on IQVIA's numbers, only about a third are still taking the medicine at 13 months. Every discontinuation is lost revenue and often regained weight. Anything that keeps a patient engaged and feeling progress on days when the scale is flat is worth a great deal to the manufacturer. A ring that says your resting heart rate has fallen and your sleep has improved is telling the truth and also making a sale.
This is why the equity investment matters more than the partnership did. A partner is a vendor you can drop. An equity holder is a stakeholder in the other company's strategy and its valuation. When the maker of the drug owns part of the maker of the instrument that measures the drug's effects, the relationship between measurement and marketing needs to be governed explicitly rather than assumed. To be fair to both, they said at the outset that data would not flow between them, and I have no reason to doubt it. But a policy is not an architecture, and the useful question is not what it says today but what would have to happen for it to change.
Step back, and the pattern is clear. LillyDirect launched in January 2024, added a nutrition partner, Nourish, that November, a behavioral health partner, Thrive Global, the following January, then retail pickup, and now wearables. Its competitors are building the same thing from the other end: digital health platforms that started with consultations and are moving toward pharmacy, labs, and their own algorithms. Both are converging on a single destination: an ecosystem in which diagnosis, prescription, delivery, and monitoring are handled by a single commercial entity, with the patient at the center and the independent clinician somewhere off to the side.
For this region, the relevance is immediate. Gulf adoption of wearables is among the highest in the world, our obesity prevalence likewise, and GLP-1 demand here has run ahead of the systems meant to supervise it. A ring that tracks a patient through therapy is an excellent thing in a market where follow-up is thin. But three questions should be settled first: where the physiological data of Saudi patients is stored and under whose jurisdiction, given that the Personal Data Protection Law has been fully enforceable since September 2024 and SDAIA has yet to publish an adequacy list, so each transfer abroad still needs its own approved safeguard, whether the insight a patient receives comes from a clinical model or a commercial one, and who is accountable when the device is wrong.
None of this makes the ring a bad instrument. Continuous physiological monitoring is among the more useful developments of the past decade, and a better source of evidence than the annual check-up it may replace.
Dear reader, the caution is narrower than a rejection. The value of a measurement depends on the independence of whoever is holding the instrument. When the company that sells the treatment also owns a share of the device that tells you the treatment is working, nothing has necessarily gone wrong, but something has certainly changed, and it deserves to be said out loud rather than discovered later.